Business Standard

Bharat Bio working on TB vaccine, to ink pact with a firm for technology

Without providing details on the name of the firm with which BBIL will be inking MoU, Ella said the TB vaccine is currently undergoing phase 3 clinical trials

Bharat Biotech, Covaxin

Photo: Shutterstock

Press Trust of India Hyderabad
: COVID-19 vaccine Covaxin maker Bharat Biotech International Limited is in the process of bringing out a vaccine against tuberculosis and soon the firm will sign a MoU with another firm for technology.
"Our honourable Prime Minister (Narendra Modi) has got an agenda of 2025 for the eradication of tuberculosis. I think we are in that direction. But we don't have the technology so we are partnering with somebody else. On that matter we should be announcing soon," Krishna Ella, Chairman and Managing Director, Bharat Biotech in panel discussion as part of BioAsia 2022 said.
Without providing details on the name of the firm with which BBIL will be inking MoU, Ella said the TB vaccine is currently undergoing phase 3 clinical trials.
He said the immunology of the nasal vaccine being developed by the company against COVID-19 has been established.
Bharat Biotech had last month said BBV154 (Nasal vaccine) received approval for phase 3 clinical trials which will evaluate the jab for both the two-dose primary schedule and booster dose schedule.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 24 2022 | 7:42 PM IST

Explore News